drugset / Trial / NCT00435526
Efficacy of Anti-CFA/I and CfaE Bovine Milk Immunoglobulin Against Challenge With H10407 ETEC Expressing CFA/I
Phase 1
Completed
30 enrolled
Johns Hopkins Bloomberg School of Public Health
Naval Medical Research Center · collabWalter Reed Army Institute of Research (WRAIR) · collab
RandomizedSingle-groupDouble-blindPrevention
Summary
The purpose of this study is to assess anti-CFA/I and anti-CfaE BIgG safety and to determine protective efficacy of anti-CFA/I and anti-CfaE BIgG against diarrhea after challenge with H10407, a CFA/I-expressing ETEC strain.
Timeline
- Start
- 2006-03
- Primary completion
- —
- Completion
- 2006-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CFA/I bovine IgG | Protein / enzyme biologic | — | Oral |
| Subject | anti-CfaE bovine IgG | Protein / enzyme biologic | — | Oral |